0000000000550562

AUTHOR

Kristina Blaslov

showing 2 related works from this author

Association between symptoms of depression, diabetes complications and vascular risk factors in four European cohorts of individuals with type 1 diab…

2020

Aims: To investigate the association between depressive symptomatology and health markers in type 1 diabetes. Methods: Four countries from the InterDiane Consortium had adopted the Finnish Diabetic Nephropathy Study protocol, including the Beck Depression Inventory (BDI). Associations between depression symptomatology, diabetes complications (diabetic nephropathy, proliferative retinopathy, major adverse cardiovascular events [MACE]) and vascular risk factors (metabolic syndrome, body mass index, glycaemic control) were investigated. Results: In a sample of 1046 participants (Croatia n = 99; Finland n = 314; Latvia n = 315; Lithuania n = 318), 13.4% displayed symptoms of depression (BDI sco…

MaleEndocrinology Diabetes and MetabolismDISEASEDiabetic nephropathy0302 clinical medicineEndocrinologyRisk FactorsGLYCEMIC CONTROLSurveys and QuestionnairesPrevalence030212 general & internal medicineDepression (differential diagnoses)2. Zero hungerDepressionGeneral MedicineMiddle AgedMetabolic syndrome3. Good healthEuropeType 1 diabetesFemaleHEALTHAdultmedicine.medical_specialty030209 endocrinology & metabolismRETINOPATHYDiabetes Complications03 medical and health sciencesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansVascular DiseasesType 1 diabetesbusiness.industry616.379-008.64 [udc]Beck Depression InventoryADULTSCAREmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 13121 General medicine internal medicine and other clinical medicineDepression ; Diabetes complications ; Metabolic syndrome ; Type 1 diabetesDiabetes mellitus type 1 ; psychology ; Depression ; Diabetes complications ; Metabolic syndrome ; Cross-sectional studiesSelf ReportMetabolic syndromebusinessBody mass indexMace
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct